Finance
Boehringer Ingelheim 2024 sales up forex-adj 6.1%
Published by Global Banking & Finance Review®
Posted on April 2, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 2, 2025
1 min readLast updated: January 24, 2026
Boehringer Ingelheim's 2024 sales rose 6.1% currency-adjusted, driven by Jardiance and Ofev. The company anticipates slight revenue growth in 2025.
By Patricia Weiss
INGELHEIM, Germany (Reuters) -Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.
Group sales reached 26.8 billion euros ($28.94 billion), the family-owned, unlisted drugmaker said in a statement.
Boehringer's Jardiance group of products, managed in a partnership with Eli Lilly, made 8.4 billion euros in annual sales, a currency-adjusted increase of 14.6%.
Jardiance, used to treat diabetes, heart failure and chronic kidney disease, competes with AstraZeneca's Farxiga.
Annual sales of Boehringer's pulmonary fibrosis drug Ofev rose a currency-adjusted 8.9% to 3.8 billion euros, it added.
Boehringer is in a collaboration with Denmark's Zealand Pharma to develop a weight loss drug that the partners hope can be launched over the next few years, to compete with Lilly's recently launched obesity drug Mounjaro.
For 2025, Boehringer said it expects a slight increase in group revenues, adjusted for currency swings and one-off effects.
($1 = 0.9261 euros)
(Writing by Ludwig BurgerEditing by Madeline Chambers)
The article discusses Boehringer Ingelheim's 2024 sales performance, highlighting a 6.1% increase driven by key drugs.
Jardiance achieved a 14.6% increase in sales, contributing significantly to Boehringer Ingelheim's revenue growth.
Boehringer Ingelheim expects a slight increase in group revenues for 2025, adjusted for currency and one-off effects.
Explore more articles in the Finance category
